Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2026)

Alnylam Pharmaceuticals has reported Current Leases for 8 years, with the latest figure at $45.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 0.76% year-over-year to $45.7 million; the trailing twelve-month figure through Mar 2026 stood at $45.7 million (down 0.76% YoY), and the FY2025 full-year result was $45.5 million, up 8.67% from the prior year.
• Current Leases for Q1 2026 stood at $45.7 million, roughly flat from $45.5 million in the prior quarter.
• The five-year high for Current Leases was $46.1 million in Q2 2025, with the low at $41.2 million in Q2 2022.
• Historically, Current Leases has averaged $42.9 million across 5 years, with a median of $42.0 million in 2022.
• Annual changes were most pronounced in 2024 — Current Leases retreated 3.21% — and 2025, when it climbed 10.66%.
• Alnylam Pharmaceuticals' Current Leases stood at $42.0 million in 2022, then fell by 1.09% to $41.5 million in 2023, then rose by 0.91% to $41.9 million in 2024, then climbed by 8.67% to $45.5 million in 2025, then advanced by 0.31% to $45.7 million in 2026.
• The last three Current Leases figures came in at $45.7 million (Q1 2026), $45.5 million (Q4 2025), and $44.8 million (Q3 2025), per Business Quant data.